Background: Head and neck sarcoma represent about less than 10% of all body sarcoma, maxillary bone sarcoma is not a common variant among cases of head and neck sarcoma usually occur in 3rd to 4th decades of life, osteosarcoma is the most common variant among maxillary bone sarcomas, surgery isthe standard treatment line of maxillary bone sarcoma. Patients and methods: A retrospective study was conducted among 20 patients with maxillary bone sarcoma in NCI, Cairo University, during the period from 2009 to 2018 to present the experience of National cancer institute, Cairo University, in the evaluation and management of maxillary bone sarcoma. Results: among 20 cases of maxillary bone sarcoma; 11 patients (55%) were below 30 years old, 9 patients (45%) were above 30 years old. Out of our 20 patients, there were 13 males (65%) and 7 females (35%). Osteosarcoma was diagnosed in 12 patients (60%), Chondrosarcoma was diagnosed in 6 patients (30%) while Ewing's sarcoma was diagnosed in 2 patients (10%). On uni-variant analysis tumor size and adjuvant chemotherapy intake have statistically significant effect on overall survival. On Multi variant analysis, tumor size was the only predictor that had significant effect on overall survival. On uni-variant analysis tumor size had significant effect on disease free survival. On multi variant analysis tumor size only that affected the disease free survival with statistical significance.